Celiac Disease Plasma
Human plasma from clinically confirmed celiac disease donors, processed within one day of collection. Celiac disease is autoimmune with a dietary trigger: gluten peptides deamidated by transglutaminase 2 and presented via HLA-DQ2/DQ8. Supports gluten-response cytokine work, mucosal healing markers and malabsorption metabolomics. Stratifiable by tTG-IgA status, Marsh grade and gluten-free diet adherence.
Celiac Disease Plasma for Gluten-Driven Autoimmunity Research
Celiac Disease Plasma is collected from IRB-consented donors clinically diagnosed with celiac disease and processed within hours of collection to preserve cytokines, proteins and metabolites. Celiac disease is a genuine autoimmune condition with an unusual feature: the driving antigen is dietary. Gluten peptides are modified by the host enzyme transglutaminase 2, presented by HLA-DQ2 or HLA-DQ8, and drive both a T-cell response against gluten and an autoantibody response against transglutaminase 2 itself. Bulk plasma is also available.
Why Plasma for Celiac Disease
Serology defines the diagnosis, but plasma is where the dynamic, mechanism-level readouts live — the cytokines, metabolites and barrier markers that change with gluten exposure and dietary adherence.
- Gluten challenge cytokine kinetics — one of the most striking findings in celiac immunology is that a systemic cytokine response, notably IL-2, is detectable in blood within hours of gluten ingestion in treated patients, giving a functional readout of gluten-reactive T cells that plasma is well suited to capture.
- Intestinal barrier and enterocyte damage — circulating markers of enterocyte injury and permeability are studied as non-invasive alternatives to repeat biopsy for monitoring mucosal recovery.
- Metabolomic consequences of villous atrophy — malabsorption alters circulating micronutrients, lipids and amino acids; untargeted metabolomics performs better in anticoagulated plasma than in serum, where clotting and platelet release distort the metabolite profile.
- Dietary adherence biology — because the only established treatment is gluten withdrawal, plasma from donors with documented adherence versus ongoing exposure lets treated and actively triggered states be compared directly.
- HLA-restricted mechanism — nearly all celiac patients carry HLA-DQ2 or DQ8, so plasma studies gain considerable power when paired with genotype and with the PBMC or T-cell products for antigen-specific work.
- Plasma-specific analytes — cell-free DNA, complement components and coagulation-sensitive proteins require anticoagulated plasma rather than serum.
Donor Stratification Available
- Anti-transglutaminase 2 IgA serostatus and titre category where reported, and anti-deamidated gliadin peptide status where available
- HLA-DQ2 and HLA-DQ8 genotype where available
- Biopsy confirmation and Marsh grade where recorded
- Dietary status: newly diagnosed and gluten-exposed, versus established gluten-free diet with duration and documented adherence
- Presentation: classical gastrointestinal, non-classical or extraintestinal, or refractory celiac disease
- Associated autoimmune conditions: type 1 diabetes, autoimmune thyroid disease, dermatitis herpetiformis
- Matched healthy controls available, age- and sex-matched on request
Product Features
- Research Use Only (RUO)
- Celiac disease plasma collected from clinically confirmed donors
- Processed within one day of collection
- Anticoagulant of choice (EDTA, sodium citrate, heparin) available on request
- IRB-approved protocols and informed consent
- Custom aliquot volumes available upon request; volumes reported per lot
De-identified Donor Data
- Verified celiac disease diagnosis
- Demographic data: age, sex assigned at birth, race/ethnicity
- Donor-reported medications, allergies and comorbidities
- Serology, biopsy findings and dietary status where available
- Additional celiac disease-specific metadata available on request
Applications
- Cytokine profiling and gluten-response biomarker research
- Non-invasive markers of mucosal healing and intestinal permeability
- Untargeted and targeted metabolomics of malabsorption
- Proteomic and multiplex immunoassay panel development
- Dietary adherence monitoring biomarker discovery
- Nutrient deficiency and micronutrient status research
- Drug development for non-dietary celiac therapies, including transglutaminase 2 inhibition and tolerance induction
- Cell-free DNA and complement analyte studies
Other Celiac Disease Specimen Types
- Celiac Disease Serum — the preferred matrix for tTG-IgA and endomysial antibody serology
- Celiac Disease Whole Blood
- Celiac Disease PBMC
- Celiac Disease Leukopak
- Celiac Disease CD4+ T Cells
- Celiac Disease Bulk Plasma
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Celiac disease plasma is available in standard and custom volumes. For pricing, availability or a specific stratification request, email learnmore@sanguinebio.com; please also contact us for international orders or documentation requirements to ensure compatibility with your country’s regulations. To browse availability across all disease states, visit our human plasma page.
Protocols & Documentation
-
Download
Plasma Isolation
Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Plasma
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.